Auph short interest.
Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at the bottom.
Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Back to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...WebJan 29, 2021 · AUPH Short Interest SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 02/12/2021 5,442,521 4,199,973 1.295847. Reply Like. Delmar Price. 26 Feb. 2021. Investing Group.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.WebAUPH fails-to-deliver data, short interest, short sale transactions, short volume, borrow rates, short shares availability and much more information. Help Login Register Trading System Live Account. Ticker: ... AUPH. Trading System Performance for AUPH. Appeared in Fisher Transform Cross Up screen on 2023-02-17 2023-02-08: Short Sale Restricted ...
Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...
Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...It seems like the purpose of the document is to formalize the recent changes to the commercial partnership (originally announced here) as well as some of the items from the cooperation agreement released in February; particularly when it comes to the availability of stock warrants that Healios can execute once they achieve approvals for ARDS ... As of March 31, 2023, Aurinia held cash, cash equivalents, and short-term investments of $361.5 million, down from $389.4 million at the end of 2022 due to continued investments in commercial ...Today's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.08 beats by $0.11.; Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...
Aug 24, 2022 · Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...
The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...
Nov 2, 2023 · Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ... 3 Agu 2023 ... The increase in other income is primarily related to change in fair value assumptions driven predominantly by rising interest ... short-term ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comAUPH: Aurinia favored at Cantor despite earnings miss • 2:25 PM. Aurinia Pharmaceuticals (AUPH -18.2%) has plunged after the company’s Q1 financials came below expectations.Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...
AUPH: Aurinia favored at Cantor despite earnings miss • 2:25 PM. Aurinia Pharmaceuticals (AUPH -18.2%) has plunged after the company’s Q1 financials came below expectations.Are you a smaller woman looking for a new hairstyle? Short haircuts can be a great way to make a bold statement and show off your features. But with so many options available, it can be hard to know which one is right for you.May 11, 2023 · AUPH is currently averaging 3,052,205 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interest
Aurinia Pharm Ord (AUPH) Company Description. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental …Web
Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dLive Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPH3 Agu 2023 ... The increase in other income is primarily related to change in fair value assumptions driven predominantly by rising interest ... short-term ...M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ...Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...
View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.
The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other areas of their business on a regular ...
Today's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …Global Coverage. Comprehensive ownership data of US Institutions, Mutual Funds, and ETFs targeting equities and bonds in mature, emerging, and frontier markets. Activist Investor 13D Filings. Beneficial Ownership 13G Filings. Institutional Ownership 13F Filings. Insider 3, 4 and 5 Filings.WebDec 10, 2021 · Aurinia Pharmaceuticals (NASDAQ: AUPH) is trading ~2.5% higher in the pre-market after Oppenheimer raised its recommendation on the stock to Outperform from Perform. The price target of $31 per ... Today's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …This page provides short interest, short volume, short volume ratio, short borrow rates, and short squeeze score for the security. US: AUPH / Aurinia Pharmaceuticals Inc - Insider Trading Report This page provides data on the corporate insiders of Aurinia Pharmaceuticals Inc and their trades, trade performance, and predictive analysis.Biocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebIn this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.Nov 2, 2023 · Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ... Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ...AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR).
9 Des 2019 ... (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage ... short form base shelf prospectus (the “Base Shelf Prospectus”) dated ...2023-03-10 Short sale volume (not short interest) for $AUPH is 38%. http://shortvolumes.com/?t=AUPH $AEZS 37% $REGN 56% $XLV 46%. 11 Mar 2023 12:54:01Web@PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...Aurinia Pharma ( NASDAQ: AUPH) is scheduled to announce Q3 earnings results on Thursday, November 2nd, before market open. The consensus EPS Estimate is -$0.17 vs -$0.06 in 3Q22 and the consensus ...Instagram:https://instagram. stock price of plug powerai company stockvsolwhat gold stock to buy Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options... best lender for va loanbest cheap stocks buy Aurinia Pharma ( NASDAQ: AUPH) is scheduled to announce Q3 earnings results on Thursday, November 2nd, before market open. The consensus EPS Estimate is -$0.17 vs -$0.06 in 3Q22 and the consensus ... voo yield Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dThe European Commission has approved Aurinia Pharmaceuticals' ( NASDAQ: AUPH) Lupkynis (voclosporin) for lupus nephritis. The approval triggers a $30M milestone payment from partner Otsuka ...M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest